PROSTATE-SPECIFIC ANTIGEN RESPONSE TO DEFERRED COMBINED ANDROGEN BLOCKADE THERAPY USING BICALUTAMIDE PREDICTS SURVIVAL AFTER SUBSEQUENT OESTROGEN AND DOCETAXEL THERAPIES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER

Authors

  • Marc B. Garnick


The authors have made the intriguing observation that a PSA response in patients to bicalutamide, sequentially added to LHRH therapy at the time of relapse, potentially has the ability to predict subsequent response to both oestrogen and docetaxel chemotherapy. Although retrospective and small, their study does provide a testable hypothesis that could alter the manner in which the multitude of hormonal therapies are sequenced in future practice. Again, the retrospective nature of the study needs to be respected – there should not be an unbridled embracing of practice change – but this emphasizes the need for a study that could either support or refute the findings.

Ancillary